Gynaecology Research and Publication
Details of Research
- Funded Project
Duration: January 2019 to December 2022(Excluding Clinical Trials)
| Funded Projecrt | ||||||||
|
Sr. No.
|
Title of Project |
Proposal No. (IEC No.)
|
Name of Principle Investigator
|
Amount of Grant Received
|
Name of Funding Agency |
Collaboration with other institute (if any) |
Status of Project (Ongoing/ Completed) |
Publication (YES/NO) |
|
1 |
The Effect of Levonorgestrel releasing intrauterine system on uterine blood flow in patients with heavy menstrual bleeding |
IEC/ Pharmac/2021/322 |
Dr. Avantika Gupta |
60,000/- |
Intramural Institute |
None |
completed |
Yes |
Duration: January 2024 to December 2024 (Excluding Clinical Trials)
| Funded Projecrt | ||||||||
|
Sr. No.
|
Title of Project |
Proposal No. (IEC No.)
|
Name of Principle Investigator
|
Amount of Grant Received
|
Name of Funding Agency |
Collaboration with other institute (if any) |
Status of Project (Ongoing/ Completed) |
Publication (YES/NO) |
|
1 |
Development, implementation and evaluation of Protocolized Cardio-Obstetric CAre in improving maternal Cardiac, obstetric and fetal outcomes of Pregnant Women with Heart Diseases in INDIA. aka – National Pregnancy And Cardiac diseases – INDIA Study Group (NPAC INDIA) |
IEC/Pharmac/2024/798 dated 30/03/2024 |
Dr Arijit kumar Ghosh |
9,84,268/- |
ICMR |
Yes |
Ongoing |
No |
|
2 |
Validating PIWIL mRNAs and their protein signatures as a predictive marker for fertilizing competence of the sperm in assisted reproductive technology –a multicentric cohort study |
IRPIG-2024-01-01230 |
Dr Gugapriya |
2.5 crores |
ICMR |
Yes |
Ongoing |
No |
|
3 |
Comparison of Effectiveness of Continuous vs. Stepwise Implementation Approaches for 6-Month Lifestyle Medicine Interventions among Polycystic Ovarian Syndrome Patients: A Multicentric Randomized Controlled Tria |
IIRPIG-2024-01-01915 |
Dr Prathmesh |
2.85 Cr |
ICMR |
Yes |
Not started yet |
No |
|
4 |
Oral Mifepristone Versus Foley’s catheter for pre-induction cervical ripening in term pregnancies – an open label randomized controlled trial.
|
IEC/Pharmac/2024/1077 |
Dr Medha Davile
|
80,900
|
AIIMS Nagpur |
No |
On going |
|
Duration: January 2025 to till date (Excluding Clinical Trials)
| Funded Projecrt | ||||||||
|
Sr. No.
|
Title of Project |
Proposal No. (IEC No.)
|
Name of Principle Investigator
|
Amount of Grant Received
|
Name of Funding Agency |
Collaboration with other institute (if any) |
Status of Project (Ongoing/ Completed) |
Publication (YES/NO) |
|
1 |
Center for Advanced Research in Hypertensive Disorders of Pregnancy.(5 years) |
IEC/Pharmac/2025/ |1622,17/10/2025
|
PI: Dr Shuchita Mundle
|
19,85,164 (10 months)
|
ICMR |
JIPMER, Pondicherry |
On going |
|
|
2 |
Optimising Letrozole Dose and Duration for Ovulation Induction in Infertile Women with PCOS: A Multicentric, Triple-Blind, Placebo-Controlled RCT (OLIO-PCOS Trial). |
IIRPSG-2025-01-06068 |
Dr Anita Yadav |
16,40,553/- |
ICMR |
yes |
Not started yet |
|
|
3 |
AI-Powered Prediction of Preeclampsia: Cardiovascular Profiling Using Wearables, Echocardiography and Biomarker at 28-32 Weeks of Pregnancy for Predicting Late-Onset Preeclampsia |
Under review |
Dr.Shuchita Mundle |
22,49,520 |
BFI-BIOME Support for Advancement in Medical and Applied Research for Transformative Healthcare (SAMARTH) Grant Program.
|
JIPMER Pondicherry and IIT Bombay |
Not started yet |
|
- Clinical Trials
|
Sr. No.
|
Title of Project |
Clinical Trial No.
|
Name of Principle Investigator
|
Amount Received
|
Sponsors |
Status of Project (Ongoing/ Completed) |
Publication (YES/NO) |
|
1 |
A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of RSV MAT (RSVPreF3) vaccine (GSK3888550A), administered IM to healthy pregnant women 18 to 49 years of age, for prevention of RSV LRTI in their infants up to 6 months of age” |
18/03/2021 IECCT/Pharmac/2021/57,Date:18/3/21
|
Dr. Shuchita Mundle |
3.22Cr |
GSK Pharmaceuticals |
Completed |
Yes |
|
2 |
A real-world prospective study to evaluate the geographical distribution of prevalence, sensitization rate, and utilization of prophylactic treatment of Rh-negative women in India. |
IECCT/Pharma/2022/186,dated,26/09/2022 |
Dr. Shuchita Mundle |
1,50,000 |
Bharat Serum and Vaccines |
Completed |
Yes |
|
3 |
A non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009 (n=15), RSV MAT-012 and RSV MAT-039) during any pregnancy conceived post vaccination/control. |
IECCT/Pharma/2023/210,dated,14/03/2023 |
Dr. Shuchita Mundle |
4,59,418.84 |
GSK Pharmaceuticals |
Completed |
No |